Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab plus statin versus statin alone in ischemic stroke
ChiCTR2200066354Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Soochow University
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of alirocumab in ischemic stroke (2 arms), sponsored by The Second Affiliated Hospital of Soochow University. Primary endpoints: First fatal or non-fatal stroke, First fatal or non-fatal myocardial infarction and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
alirocumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2200066354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066354.